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Abstract The p21-activated kinase (PAK) family is homolo-
gous to the yeast sterile 20 (Ste20) and regulates a wide variety
of cellular responses, including cell morphology, proliferation,
and survival. In this study we examined the activation of PAK1
by GLQ subunits. Co-transfection of COS7 cells with GL1Q2 or
GL1Q5 was su⁄cient to induce agonist-independent activation of
PAK1. Expression of dominant/negative Rac, Cdc42, or Ras did
not inhibit this GLQ-dependent activation. Wortmannin, which
inhibits phosphoinositide 3-kinase (PI3-kinase) activity, and ex-
pression of a dominant/negative form of Akt were su⁄cient to
abrogate the activation of PAK1 that was induced by GLQ.
These results reveal that stimulation of PAK1 by GLQ can occur
via a PI3-kinase and Akt pathway that does not require Rac1 or
Cdc42.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The protein kinases of the mitogen-activated protein kinase
(MAPK) family are a highly conserved group from yeast to
man. MAPKs phosphorylate speci¢c serines and threonines of
various target proteins and regulate cellular activities such as
proliferation, cytoskeletal rearrangement, and cell survival [1^
3]. There is evidence that activation of MAPK cascades can
follow phosphoinositide 3-kinase (PI3-kinase) stimulation de-
pending on the cell type and stimulus used [4,5]. The phos-
phorylated lipids produced by activated PI3-kinase, predom-
inantly phosphatidyltinositol 3, 4, 5 trisphosphate (PIP3) and
PI(3,4)P2, activate downstream protein kinases Akt and PDK.
PIP3 and PI(3,4)P2 bind with high a⁄nity and speci¢city to
the PH domain of Akt [6]. This binding induces translocation
of Akt to the plasma membrane and subsequent phosphory-
lation of Thr-308 and Ser-473 [7^9].
In addition to Akt, the Rho GTPases Rac1 and Cdc42 have
been identi¢ed as downstream e¡ectors of PI3-kinase [10,11].
The Rho family GTPases link the plasma membrane receptors
to the assembly and organization of the actin cytoskeleton.
The Rho GTPase cascade has been shown to be activated at
di¡erent points by various extracellular stimuli [12]. The for-
mation of actin stress ¢bers can be achieved by treatment
of quiescent cells with lysophosphatidic acid (LPA), while
growth factors such as PDGF and insulin stimulate polymer-
ization of actin at the plasma membrane of many cell types to
induce lamellipodia formation and surface ru¥ing in a PI3-
kinase-dependent manner [13]. The activation of Cdc42 and
Rac can stimulate the activity of downstream e¡ectors, such
as a family of serine^threonine kinases: p21-activated kinases
(PAKs) [14^17].
Screens for binding partners of Rac and Cdc42 GTPases in
rat brain slices revealed that a member of the Ste20-like ser-
ine^threonine protein kinase family, PAK, could bind and be
activated by GTP bound forms of these GTPases [16]. In
Saccharomyces cerevisiae, Ste20 is stimulated by GLQ subunits
(Ste4/Ste18) in response to mating pheromones [18,19]. PAKs
1, 2, and 3 comprise the Group I PAKs and PAKs 4, 5, and 6
comprise the Group II PAKs. In mammalian tissues PAK1 is
highly expressed in brain, muscle, and spleen; PAK2 is ex-
pressed ubiquitously, PAK3 is expressed in the brain [20],
PAK4 is expressed in most tissues, with high levels of expres-
sion in the testis and colon [21,22], PAK5 is expressed in the
brain [23], and PAK6 is expressed at the highest level in the
testis and prostate [24]. All PAK proteins identi¢ed to date
share a similar N-terminal motif stretching over 18 amino
acids that binds to Cdc42 and Rac and is termed the
Cdc42/Rac-interactive binding domain (CRIB) [25,26]. Group
I PAKs have an autoinhibitory domain (AID) that overlaps
the CRIB domain, this AID is lacking in the Group II PAKs.
The activation of Group I PAKs is enhanced when GTP-
bound Rac or Cdc42 bind the CRIB domain. The activation
of the Group II PAKs is distinct, however, as they are inde-
pendent of Rac/Cdc42 binding [21,23,24].
In this study we investigated the role of GLQ subunits in
PAK1 activation. Cells that overexpress G protein L1Q5 and
GL1Q2 subunits have agonist-independent activation of PAK1
that is insensitive to dominant-negative Rac1 or Cdc42.
This GLQ-dependent activation was also insensitive to a selec-
tive epidermal growth factor receptor (EGFR) inhibitor,
AG1478, and a protein kinase C (PKC) inhibitor, bisindolyl-
maleimide (BIS), but was sensitive to an inhibitor of PI3-ki-
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nase, wortmannin, and to expression of dominant-negative
Akt. Our results support a model where PAK1 can be stimu-
lated by GLQ subunits via PI3-kinase and Akt, but indepen-
dently of Rac and Cdc42.
2. Materials and methods
2.1. Plasmids and antibodies
Antibodies to the N- and C-terminus (N20 and C19) of PAK1 were
purchased from Santa Cruz Biotechnology, with the former used for
immunoprecipitation and the latter for Western blotting. The anti-
bodies to PhosphoPAK1 (Thr-423)/PAK2 (Thr-402), to PhosphoAkt
(Ser-473), and to total Akt were purchased from Cell Signalling Tech-
nology. Plasmids used in this study include pCDhM2 [27], pRK7myc-
PAK1 prepared from pCMV6mycPAK1 plasmid (that was a kind gift
from Dr. Gary Bokoch) by subcloning a BamHI/EcoRI fragment into
pRK7, pRK5GL1, pRK7GQ2, and pRK7GQ5 and pKH3 with inserts
for RacN17, Cdc42N17, and RasN17 [27]. The pKH3 plasmid ex-
presses inserts with a triple haemagglutinin (HA) epitope tag at
the N-terminus as described previously [12,28]. Plasmids expressing
dominant-negative Akt, pCMV6.HA.Akt.K/M and active Akt,
pCMV6.myr.Akt.HA, were kind gifts from Dr. Alex Toker.
2.2. Cell culture and transfection assays
COS7 cells were cultured as described previously [28^30]. COS7
cells were transfected by calcium phosphate precipitation with 2 Wg
pRK7myc-PAK1 plasmid and 3 Wg vector control or test plasmids
[30]. Cells were grown for 48 h after transfection. Cells that were
treated with LPA were serum starved for 24 h prior to treatment
with the agonist.
2.3. Agonist treatment and immunoprecipitation for COS7 transfectants
The COS7 cells were treated with agonists and inhibitors and then
the PAK1 immunoprecipitated as described [31]. PAK1 activity was
assayed [32] with modi¢cations as described [31]. Representative re-
sults are shown with data reported as meanLS.E.M. from three in-
dependent experiments. Whole cell lysates for Western blotting of
endogenous PAK and Akt (Fig. 6) were prepared as described [29].
3. Results
3.1. Activation of PAK1 by GLQ subunits can occur in the
presence or absence of agonist stimulation
In yeast models it has been noted that Ste20, a PAK ho-
mologue, binds to and is activated by GLQ subunits [17,18].
To investigate the potential role of GLQ in cell signaling
through PAK1 in mammalian cells, we co-transfected COS7
cells with mycPAK1 and combinations of GL1Q5 or GL1Q2.
Overexpression of GL1Q5 or GL1Q2 yielded a 4.2-fold increase
in PAK1 activity when compared to control mycPAK1 trans-
fectants. Treatment of the GL1Q2 or GL1Q5 co-transfectants
with LPA did not signi¢cantly further elevate the level of
PAK1 activity. Similarly, carbachol, EGF, and phorbol 12-
myristate 13-acetate (PMA) were also unable to increase
PAK1 activity beyond that induced by GL1Q5 (Fig. 1). These
results reveal that overexpression of GLQ subunits is su⁄cient
to induce PAK1 activation.
3.2. Inhibition of PI3-kinase decreases GLQ activation of PAK1
Overexpression of GLQ results in activation of PAK1. To
investigate whether this stimulation was dependent on the
activity of intermediate kinases, cells co-transfected with
GL1Q5 and mycPAK1 were incubated with selective inhibitors
of PI3-kinase or EGFR or PKC for 30 min prior to cell lysis.
No inhibition of GLQ-dependent PAK 1 activation was de-
tected following AG1478 or BIS administration (Fig. 2),
although these inhibitors will block EGF or phobol ester-de-
pendent PAK1 activation [31]. Inhibition of PI3-kinase by
wortmannin reduced the GLQ-dependent activation of PAK1
from 4.2- to 1.4-fold over control (Fig. 2). We have previously
shown that wortmannin does not by itself inhibit PAK1 ac-
tivity, as it did not reduce phorbol ester- or LPA-dependent
PAK1 activation [31]. The inhibition by wortmannin therefore
indicates that GLQ requires PI3-kinase to activate PAK1 in
these cells. This result also suggests that PAK1 activation
by GLQ is mediated through a reversible mechanism, since
the wortmannin is only present for the last 30 min of the
incubation of the co-transfected cultures.
3.3. GL1Q5 activation of PAK1 is independent of Rac, Cdc42,
and Ras
To investigate the role of Rac/Cdc42 binding to the N-ter-
minal CRIB domain of PAK1 in the GLQ-dependent activa-
tion, dominant-negative HARacN17 or HACdc42N17 were
overexpressed in GL1Q5/PAK1 co-transfectants. Surprisingly,
the overexpression of dominant-negative Rac or Cdc42 did
not inhibit the activation of PAK1 (Fig. 3), indicating that
the activation of PAK1 by GL1Q5 is independent of the inter-
action of these GTPases with the CRIB domain of PAK1.
Fig. 1. Activation of PAK1 by GLQ subunits can occur in the pres-
ence or absence of agonist stimulation. COS7 cells were transfected
with mycPAK1 and GL1Q5 or GL1Q2 (plus hM2 for those to be
stimulated with carbachol) and then treated as shown. A: Overex-
pression of GL1Q5 or GL1Q2 increased PAK1 activity when com-
pared to untreated mycPAK1 transfectants. Western blots of the im-
munoprecipitates were probed with 9e10 antibody to detect myc-
tagged PAK1. pRK7 plasmid was used as a negative vector control
(3ve). MBP was used as a substrate to detect PAK1 phosphoryla-
tion in an in vitro kinase assay. B: Graph depicting activation of
PAK1 in cells co-transfected with GLQ subunits.
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Under these same conditions, expression of dominant-nega-
tive Rac1 or Cdc42 is su⁄cient to completely block LPA
(shown) or EGF or phorbol ester stimulation of PAK1 [31].
Co-transfections with dominant-negative Ras, HARasN17,
also failed to inhibit GLQ-dependent PAK1 activation, sug-
gesting that Ras activation is also not required.
3.4. GL1Q5 activation of PAK1 occurs through Akt
It has been established that Akt is a downstream e¡ector of
PI3-kinase [33^35]. We therefore investigated the role of Akt
in PAK1 stimulation by GLQ. Co-transfection of mycPAK1
and a constitutively active Akt (myrAkt) revealed an activa-
tion of PAK1 that was similar to that induced by GL1Q5 (Fig.
4). The expression of dominant-negative Akt (AktK/M) in the
mycPAK1/GL1Q5 co-transfectants blocked PAK1 activation.
Stimulation of PAK1 activity was also assayed following
treatment with 200 nM PMA, which activates PAK1 via
PKC and is independent of PI3-kinase [31]. This activation
of PAK1 following PMA treatment was not abrogated by
transfection with dominant-negative AktK/M. These results
indicate a selective role for Akt in PAK1 regulation in re-
sponse to G protein LQ subunits.
3.5. Activation of endogenous PAK1 and Akt by EGF and LPA
We have previously shown that multiple agonists are able
to activate PAK1 in COS7 cells [31]. To determine whether
endogenous Akt and PAK1 are activated by the same ago-
nists, we treated COS7 cells with LPA, EGF, or with EGF
after pretreatment with wortmannin. Activation of Akt and
PAK1 was assayed by Western blotting for the phosphorylat-
ed kinases in whole cell lysates (Fig. 5). Stimulation with LPA
or EGF activated both Akt and PAK1. Inhibition of PI3-ki-
nase activity with wortmannin blocked the ability of EGF to
stimulate both Akt and PAK1. Wortmannin also blocked the
ability of LPA to stimulate Akt (data not shown), although it
does not prevent the stimulation of PAK1 by LPA [31].
3.6. Activation of endogenous PAK1 by GL1Q2 and GL1Q5
subunits
We have shown that GLQ subunits can activate a co-trans-
fected mycPAK1 construct. To determine whether endoge-
nous PAK1 could also be activated by increased GLQ, we
transfected COS7 cells and assayed for the activity of native
PAK1. There was a 3.5- and 4.8-fold increase in PAK1 activ-
ity following GL1Q2 and GL1Q5 overexpression, respectively
(Fig. 6). This activity could be inhibited by pretreatment of
the cells for 30 min with 200 nM wortmannin. We can con-
clude that endogenous PAK1 can also be stimulated by GLQ
through PI3-kinase activation.
Fig. 2. Inhibition of PAK1 activation by wortmannin. COS7 myc-
PAK1/GL1Q5 transfectants were untreated or treated with the selec-
tive EGFR inhibitor AG1478 (200 nM), the PI3-kinase inhibitor
wortmannin (200 nM), or the PKC inhibitor BIS (5 WM) for 30
min. A: MBP was used as a substrate to detect PAK1 phosphoryla-
tion in an in vitro kinase assay. Western blots of the immunopreci-
pitates were probed ¢rst with 9e10 to detect mycPAK1, then
stripped and reprobed with a PhosphoPAK1 (Thr-423)/PAK2 (Thr-
402) antibody (Cell Signalling Technology). pRK7 plasmid was used
as a negative vector control (3ve). B: Graph depicting activation of
PAK1 as observed by assay of MBP phosphorylation.
Fig. 3. GL1Q5 activation of PAK1 is independent of Rac, Ras, or
Cdc42. COS7 cells were transfected with myc-tagged PAK1 alone or
co-transfected as shown. A: MBP was used as a substrate to detect
PAK1 phosphorylation in an in vitro kinase assay. Western blots of
the immunoprecipitates were probed with 9e10 to detect myc-tagged
PAK1. Western blots of cell lysates were probed with 12Ca5 to de-
tect HA-tagged proteins. pRK7 plasmid was used as a negative vec-
tor control (3ve). B: Graph depicting activation of mycPAK1 by
GLQ in COS7 cells. The inhibition of LPA-induced PAK1 activation
by dominant-negative Rac and Cdc42 is consistent with that previ-
ously described [31].
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4. Discussion
PAKs are involved in the regulation of a wide range of
cellular activities and abnormalities of PAK function are
thus likely to contribute to various pathologies. A few exam-
ples of diseases where aberrant PAK expression and/or acti-
vation may play a role are in£ammatory diseases involving
enhanced leukocyte in£ux and activation, cancers involving
high levels of metastasis, defects in neuronal formation or
degeneration, and autoimmune disorders, developmental ab-
normalities, and cancers in which defective apoptotic cell
death plays an etiologic role [15]. Two important endpoints
of PAK signaling have emerged: nuclear events that in£uence
gene expression, and cytoskeletal events that impact upon
Fig. 4. GL1Q5 activation of PAK1 is dependent on Akt. Co-trans-
fection of mycPAK1 and a constitutively active Akt, myrAkt, and
co-transfection of mycPAK1, GL1Q5 and myrAkt in COS7 revealed
activation of PAK1. The expression of dominant-negative Akt,
AktK/M, in the mycPAK1/GL1Q5 co-transfectants inhibited PAK1
activation. A: MBP was used as a substrate to detect PAK1 phos-
phorylation in an in vitro kinase assay (top panel). Western blots of
the immunoprecipitates were probed with 9e10 to detect myc-tagged
PAK1 (middle panel). Western blots of cell lysates were probed
with 12Ca5 to detect HA-tagged proteins (bottom panel). pRK7
plasmid was used as a negative vector control (3ve). B: Stimulation
of PAK1 activity assayed following treatment with 200 nM PMA is
not blocked by dominant-negative Akt. C: Graph depicting activa-
tion of mycPAK1 in COS7 cells.
Fig. 5. Agonist activation of endogenous Akt and PAK1. COS7
cells were treated with 10 WM LPA for 15 min, or 100 nM EGF for
5 min (with or without a 30 min pretreatment with 200 nM wort-
mannin) and then whole cell extracts were prepared [29]. The sam-
ples were run in parallel for Western blotting for both active and
total populations of Akt and PAK1, as indicated.
Fig. 6. Activation of endogenous PAK1 by GLQ occurs through
PI3-kinase. Overexpression of GL1Q2 or GL1Q5 activates endogenous
PAK1 in COS7 cells. This activity is inhibited by wortmannin. Con-
trol immunoprecipitations (3ve) were performed with a rabbit anti-
mouse antibody in place of the N-20 anti-PAK antibody. A: MBP
was used as a substrate to detect PAK1 phosphorylation in an in
vitro kinase assay (top panel). Western blots of the immunoprecipi-
tates were probed ¢rst with C19 anti-PAK to detect endogenous
PAK1 (middle panel), then stripped and reprobed with a Phospho-
PAK1 (Thr-423)/PAK2 (Thr-402) antibody (second panel from top).
Ten percent of the lysates used for the immunoprecipitations were
instead subjected to TCA precipitation [30] and then processed for
Western blotting for active (phosphoSer-473) Akt (second panel
from bottom). These blots were stripped and reprobed for total Akt
(bottom panel). B: Graph depicting activation of PAK1 as observed
by the assay of MBP phosphorylation.
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cellular dynamics. While these biological endpoints provide
interesting possibilities regarding cellular signaling by Cdc42
and Rac, they also raise questions regarding the nature of
PAK regulation and the identity of downstream targets [36].
In recent years there has been a great interest in upstream
components that lead to PAK1 activation. In the present
study we show that PAK1 activation in COS7 transfectants
can occur through a Cdc42/Rac1-independent manner via
PI3-kinase and Akt.
PI3-kinases have emerged as important constituents of sig-
naling pathways. In mammalian cells, three distinct classes of
PI3-kinases have been discovered, characterized, cloned, and
found to di¡er in their activation mechanisms [35]. Members
of the PI3-kinase family have also been considered as poten-
tial participants in the oncogenic process because they control
cell cycle progression, di¡erentiation, survival, invasion and
metastasis and angiogenesis [37^39]. Receptor-regulated class
Ib p110Q/p101 PI3KQ is activated by GLQ on stimulation of
GPCRs. GLQ is considered to be the principal, direct stimulus
of GPCR-induced PI3KQ enzymatic activity. Convincing evi-
dence for this has come from reconstitution of puri¢ed pro-
teins, demonstrating that in vitro the enzymatic activity of
monomeric and heterodimeric PI3KQ is signi¢cantly stimu-
lated by GLQ [40^44]. Several lines of evidence indicate that
speci¢c combinations of G protein K, L, and Q subunits are
required for di¡erent receptors or receptor^e¡ector networks,
and that a higher degree of speci¢city for GK and GLQ is
observed in intact systems than reported in vitro [45]. There
is also evidence that PI3KL is activated by GLQ subunits in
NIH3T3 ¢broblasts and that this activated PI3KL can further
stimulate Akt activity [46]. PI3KK and PI3KL are expressed in
COS7 cells [47]. It has also been observed that PI3-kinase
activity in COS7 cell can be inhibited by wortmannin [1,48],
and that p110L rather than p110Q is involved in the produc-
tion of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 induced by LPA
[49,50].
Akt is a downstream e¡ector of PI3-kinase that is recruited
to the membrane by PtdIns(3,4)P2 and PtdIns(3,4,5)P3. Akt is
then phosphorylated at Thr-308 by phosphoinositide-depen-
dent kinase 1 (PDK-1) [51]. Subsequent to membrane local-
ization, other residues of Akt, such as Ser-473, are also phos-
phorylated to contribute to its activation [52]. PAK1 can be
activated by Rac1/Cdc42 [15^17,32] and also by Akt [53,54].
PI3-kinase activation of PAK1 has been reported earlier [55^
57], and we are able to show that in our system both PI3-
kinase and Akt are required for PAK1 activation by GLQ. Akt
has previously been reported to activate PAK1 [47,53,58], in
one case as an intermediate between Ras and PAK1 activation
[53]. Further connections between PI3-kinase and PAK1 are
supported by the observations that heregulin regulates cyto-
skeletal reorganization and cell migration through PAK1 via
PI3-kinase [59], that PAK1 is phosphorylated and activated
by PDK-1 [60], and that exposure of opossum kidney cells to
opioid agonists results in alterations of actin polymerization
through PI3-kinase activation of PAK1 that were independent
of both Rac1/Cdc42 and Akt [55].
Our results show that expression of a constitutively acti-
vated Akt (myrAkt.HA) is su⁄cient to activate PAK1, and
that Akt activation is necessary for GLQ-dependent PAK1
activation through a mechanism that is independent of
Rac1/Cdc42. Our results also show, however, that this role
for Akt is not ubiquitous for all instances of PAK1 activation.
Thus EGF activation of PAK1, which does require PI3-kinase
activity and is associated with Akt activation, is still depen-
dent on Rac1/Cdc42 activity [31]. Further, the G protein-
coupled agonist LPA can activate both Akt and PAK1, but
the e¡ects are separable as the former is inhibited by wort-
mannin and the latter is not [31]. One factor that may need to
be considered in the interpretation of these data may be the
fact that PAK1 is also regulated by its recruitment to speci¢c
subcellular locales, for example by the adaptor protein Nck
[61^63].
This investigation of the role of GLQ subunits in PAK1
activation stems from the role of GLQ activation of Ste20 in
yeast [18]. The PAK1 homologue Ste20 is involved in trans-
mitting the mating-pheromone signal from the GLQ subunits
of a heterotrimeric G protein to a downstream MAPK cas-
cade in budding yeast [19,64]. Binding of GLQ with the non-
catalytic C-terminal region of Ste20 is essential for the acti-
vation of the MAPK cascade signaling from the mating factor
receptor [18,65]. In the current study, co-transfections with
GL1Q5, GL1Q2 plus mycPAK1 demonstrated that PAK1 is
activated by the GLQ subunits. It has been reported by others
in an in vitro assay that PAK1 is inhibited by GL1Q2 subunits
[66]. In that particular study PAK1 (232^544) was incubated
with either 150 nM GKz or 200 nM myelin basic protein
(MBP) and decreasing concentrations of GLQ. The authors
did note that GLQ slightly but reproducibly stimulated
PAK1 autophosphorylation in the presence or absence of
added substrate, indicating that GLQ binds directly to PAK1
to alter its function [66]. In our study we overexpressed the
GLQ subunits in COS7 cells. We conclude from our work that
the activation of PAK1, whether endogenous or myc-tagged,
is through PI3-kinase. Thus whether direct binding of GLQ to
PAK1 is required for this activation has not been addressed,
although such association has recently been reported [67].
It is also signi¢cant that the mechanism used by GLQ sub-
units to activate PAK1 (through PI3-kinase/Akt but indepen-
dent of Rac1/Cdc42) is distinct from two other pathways that
are stimulated by the G protein-coupled agonists that we have
studied. We have previously shown that LPA stimulates a
Rho-dependent pathway to activate PAK1 in COS7 cells
[31], whereas the majority of the signaling from muscarinic
receptors to PAK1 is transduced through transactivation of
the EGF receptor [31]. Both of these G protein-coupled re-
ceptor pathways to PAK1 activation are dependent on the
activity of Rac1/Cdc42. Thus a receptor system in COS7 cells
that operates through this newly described GLQ-dependent
mechanism is yet to be described, although chemoattractant
receptor signaling in neutrophils has recently been shown to
utilize GLQ to activate PAK1 [67].
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